-
Mashup Score: 64Genomics Now | North Thames Genomic Medicine Service - 18 day(s) ago
Listen and learn about genomics in bitesize episodes! Genomics Now is a series of conversations hosted by clinicians and scientists of the North Thames Genomic Medicine Service (NTGMS). These bitesize episodes explore how clinical genomics is developing i…
Source: genomicsnow.podbean.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 52
Among patients with resected ALK-positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.).
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche's Tecentriq - 24 day(s) ago
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES- | Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer.
Source: www.fiercepharma.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3225-23 ADOPT-lung - 2 month(s) ago
Details Last Updated: Tuesday, 25 June 2024 The aim of this trial is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant treatment with platinum-based doublet chemotherapy plus durvalumab has an effect on disease-free survival in patients not achieving a complete pathological response and in the overall patient population. DFS in patients without pCR, measured from randomisation Solange Peters, Lausanne, Swi tzerland Sabine Schmid, Berne, Switzerland EU CT number:
Source: www.etop.ibcsg.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3225-23 ADOPT-lung - 2 month(s) ago
Details Last Updated: Tuesday, 25 June 2024 The aim of this trial is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant treatment with platinum-based doublet chemotherapy plus durvalumab has an effect on disease-free survival in patients not achieving a complete pathological response and in the overall patient population. DFS in patients without pCR, measured from randomisation Solange Peters, Lausanne, Swi tzerland Sabine Schmid, Berne, Switzerland EU CT number:
Source: www.etop.ibcsg.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1Environmental asbestos exposure and lung cancer - 4 month(s) ago
Apart from living near an asbestos industry site, mine, or in an asbestos-contaminated house, environmental asbestos exposure is observed in certain regions where the (natural) soil is ‘contaminated’ with asbestos (fibers). In this essay, we review the association between environmental asbestos exposure and lung cancer in Turkey. Other studies have also suggested that environmental asbestos exposure is able to increase the risk of lung cancer. Lung cancer associated with environmental asbestos exposure seems to be diagnosed at a younger age, and the risk for women is in the same range as that for men.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 22
Lung cancer in never smokers (LCINS) accounts for up to 25% of all lung cancers and has been associated with exposure to secondhand tobacco smoke and air pollution in observational studies. Here, we evaluate the mutagenic exposures in LCINS by examining deep whole-genome sequencing data from a large international cohort of 871 treatment-naive LCINS recruited from 28 geographical locations within the Sherlock-Lung study. KRAS mutations were 3.8-fold more common in adenocarcinomas of never smokers from North America and Europe, while a 1.6-fold higher prevalence of EGFR and TP53 mutations was observed in adenocarcinomas from East Asia. Signature SBS40a, with unknown cause, was found in most samples and accounted for the largest proportion of single base substitutions in adenocarcinomas, being enriched in EGFR-mutated cases. Conversely, the aristolochic acid signature SBS22a was almost exclusively observed in patients from Taipei. Even though LCINS exposed to secondhand smoke had an 8.3%
Source: www.medrxiv.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 22
Lung cancer in never smokers (LCINS) accounts for up to 25% of all lung cancers and has been associated with exposure to secondhand tobacco smoke and air pollution in observational studies. Here, we evaluate the mutagenic exposures in LCINS by examining deep whole-genome sequencing data from a large international cohort of 871 treatment-naive LCINS recruited from 28 geographical locations within the Sherlock-Lung study. KRAS mutations were 3.8-fold more common in adenocarcinomas of never smokers from North America and Europe, while a 1.6-fold higher prevalence of EGFR and TP53 mutations was observed in adenocarcinomas from East Asia. Signature SBS40a, with unknown cause, was found in most samples and accounted for the largest proportion of single base substitutions in adenocarcinomas, being enriched in EGFR-mutated cases. Conversely, the aristolochic acid signature SBS22a was almost exclusively observed in patients from Taipei. Even though LCINS exposed to secondhand smoke had an 8.3%
Source: www.medrxiv.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 5Mesothelioma research Grant applications | Erase Meso - 6 month(s) ago
Mesothelioma research grant application form for Meso collective research fund. Research fund provided by Erase Meso, Hasag and Mavis Nye Foundation.
Source: www.erasemeso.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2Meso Collective Fund 2024 | Erase Meso - 7 month(s) ago
We are thrilled to announce our collaboration with these exceptional charities – HASAG and Mavis Nye Foundation. We have pooled money to provide grants for scientific research into the maintenance or cure for mesothelioma. Our current fund totals £ 350,00 0. Our aim is to end asbestos cancer via joint funding. Our Research advisory board will be responsible for allocating funds for this exciting, jointly funded project…which launches at BTOG 17-19th April. For more information and bios on these scientifi
Source: www.erasemeso.orgCategories: General Medicine News, Oncologists2Tweet
Interested in ctDNA NGS and #LungCancer? Want to know whats going on in England about the liquid first programme and its impact? Do listen to this series of podcasts: https://t.co/stq2eMFT0U @NorthThamesGMS @generoom @AlastairGreyst2 @BTOGORG @BTSrespiratory